Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Collagen Corporation

This article was originally published in The Gray Sheet

Executive Summary

Invests $1.6 mil. in additional funds in Mountain View, California-based GenPharm International, which is developing transgenic animal technology for use in human health care products. Collagen invested an initial $2 mil. in the company in May 1993. At the same time it announced Collagen's additional stake, GenPharm said that its European subsidiary, Gene Pharming Europe B.V., has produced human collagen from transgenic mouse milk. According to GenPharm, the success in mouse milk was necessary to establish that collagen could be correctly produced at commercially meaningful levels in milk. GenPharm says it has raised close to $8 mil. in equity financing "in the last several months"
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel